reports
Edwards Lifesciences Corp: 3 directors
Three Directors at Edwards Lifesciences Corp sold/sold after exercising options/gave away 22,120 shares at between 0.000USD and 84.029USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretion...
- Dave Nicoski
- Ross LaDuke
Int'l Insights: Bullish Stocks
Remain Overweight South Korea and Taiwan We remain bullish on EM with the 7-month uptrends intact on the MSCI Emerging Markets index (local currency) and EEM-US (USD). The latest pullback in November found support precisely at the uptrend, which is something we have been discussing and expecting for months. Supports to buy on EEM-US are at the uptrend (currently $53.60) and also the $51.80-$52.35 horizontal support level. The recent 2.5-month uptrend violation on the U.S. dollar (DXY) contin...
- Dave Nicoski
- Ross LaDuke
Vermilion ETF Pathfinder: Actionable ETF research & Ideas
Expecting a Rally Through Early-2026 We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the 3-month upt...
Moody's Ratings affirms Edwards Lifesciences at Baa2; revises outlook ...
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. At the same time, we revised the outlook to positive from stable. The rating affirmation reflects our view that E...
- Dave Nicoski
- Ross LaDuke
Vermilion ETF Pathfinder: Actionable ETF research & Ideas
Nasdaq 100 and S&P 500 Breaking Out to All-Time Highs We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). Our near-term bullish outlook will remain in place as long as the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM) are above their 20-day MAs. We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the SPX is above 5700-5785. Short-term support on SP...
- Dave Nicoski
- Ross LaDuke
Vermilion ETF Pathfinder: Actionable ETF research & Ideas
S&P 500 and Nasdaq 100 (QQQ) Testing Support In our 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) (1) could not decisively break out to new highs, (2) displayed bearish false breakouts, (3) fell back into their 2+ month trading ranges, (4) violated their 1+ month uptrends, and (5) closed below their 20-day and 50-day MAs for the first time in over a month. We also said it likely means at least another 2-4 weeks of consolidation, and tha...
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Car...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Th...
- Dave Nicoski
- Ross LaDuke
Vermilion ETF Pathfinder: Actionable ETF research & Ideas
Nasdaq 100 Breaking Out -- Buy; Bullish Outlook Intact As discussed throughout the first half of January, and reiterated in our 2/3/25 ETF Pathfinder, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We also discussed our non-concern as it related to the Canada/Mexico tariff situation, calling the pullback a buying opportunity. Now, we are seeing signs that this 2+ month consolidatio...
ECH. ISHARES MSCI CHILE CAPPED INVESTABLE MARKET INDEX FUND
EWG ISHARES MSCI GERMANY ETF
MCHI.. ISHARES MSCI CHN
EWI BLACKROCK INSTITUTIONAL TRUST COMPANY N.A.
EPOL ISHARES MSCI POLAND CAPPED ETF
HEDJ WSDMTR EURP HDGD
EUFN ISHARES MSCI EUROPE FINANCIALS
EUSC WDMTR ERP HDG EQ
KWEB KRANESHARES CSI CHINA INTERNET FUND
EWW ISHARES MSCI MEXICO CAPPED INDEX FUND
ISHARES MSCI UAE CAPPED ETF
Edwards Lifesciences to Host Earnings Conference Call on February 11, ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a ...
- Dave Nicoski
- Ross LaDuke
Vermilion ETF Pathfinder: Actionable ETF research & Ideas
Tariff Tantrum Underway; Market Dynamics Still Risk-On As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity. Bottom line: market dynamics remain risk-on, and our outlook remains bullish as long as t...
EIS EISEN- UND HUETTENWERKE AG
EWG ISHARES MSCI GERMANY ETF
FDN FIRST TRUST DOW JONES INTERNET INDEX FUND
IAI ISHARES U.S. BROKER-DEALERSETF
EPOL ISHARES MSCI POLAND CAPPED ETF
HEDJ WSDMTR EURP HDGD
EUFN ISHARES MSCI EUROPE FINANCIALS
A14Y8J ARK WEB X.0 ETF NO PAR VALUE PER SHARE
ISHARES MSCI UAE CAPPED ETF
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthc...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structur...
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Confe...
NEW YORK--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), the continued long-term performance of Surgical, and future opportunities wi...
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enro...
Edwards Lifesciences to Host Earnings Conference Call on October 24, 2...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart...
Moody's Ratings affirms Edwards Lifesciences' Baa2 ratings
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. The outlook is stable. The rating affirmation reflects our view that Edwards will continue to sustain leadership an...
Moody's Ratings affirms Edwards Lifesciences' Baa2 ratings
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. The outlook is stable. The rating affirmation reflects our view that Edwards will continue to sustain leadership ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.